Retraction Note: Prognostic value of heart failure in hemodialysis-dependent end-stage renal disease patients with myocardial fibrosis quantification by extracellular volume on cardiac magnetic resonance imaging

Huayan Xu, Zhigang Yang, Yi Zhang, Wanlin Peng, Chunchao Xia, Zhenlin Li, Yong He, Rong Xu, Li Rao, Ying Peng, Yuming Li, Hongling Gao, Yingkun GuoBMC 2020 · DOI · OpenAlex

TL;DR

This document is a formal retraction of a study that used gadolinium-based contrast agents (GBCAs) to image the hearts of patients with end-stage renal disease (ESRD). While the original research aimed to predict heart failure through MRI-based fibrosis quantification, it was retracted because the specific contrast agent used is strictly contraindicated for patients with severe kidney failure due to the risk of Nephrogenic Systemic Fibrosis (NSF).

What Problem Does This Paper Address?

The original research sought to improve the prognostic toolkit for patients with end-stage renal disease (ESRD) who are dependent on hemodialysis. These patients are at high risk for heart failure, often driven by myocardial fibrosis (the scarring of heart tissue). The authors used Cardiac Magnetic Resonance (CMR) imaging to quantify this fibrosis by measuring "extracellular volume" (ECV).

However, the "problem" addressed by this specific retraction note is a critical failure in research ethics and patient safety protocols. After the paper was published, the scientific community pointed out that the study protocol utilized Gadodiamide, a gadolinium-based contrast agent. In patients with severe renal insufficiency, gadolinium exposure is a known trigger for Nephrogenic Systemic Fibrosis (NSF)—a rare, painful, and potentially fatal condition characterized by the thickening and hardening of the skin and internal organs.

Methods

In the original study, the researchers performed CMR imaging on ESRD patients. To measure myocardial fibrosis, they administered Gadodiamide to calculate the ECV.

Recognizing some level of risk (though admittedly unaware of the full contraindication at the time), the authors implemented two safety measures:

  1. Dose Reduction: They decreased the standard contrast dose given to the patients.
  2. Rapid Clearance: Patients underwent complete hemodialysis within two hours of the imaging session to flush the GBCA from their systems.

The retraction note highlights that the authors were unaware of international guidelines—which state that GBCAs should only be used in at-risk patients for essential diagnostic purposes when no alternatives exist—during the design and ethics approval phases of the study.

Datasets

The study involved a cohort of patients with hemodialysis-dependent end-stage renal disease (ESRD). Specific details regarding the size of the dataset or the specific clinical benchmarks used for heart failure prognosis are not detailed in this retraction note, as the focus is on the safety violation rather than the data itself.

Key Insights and Ideas

  • The Weight of Contraindications: Even if a study produces interesting data, the use of a contraindicated substance (Gadodiamide in renal failure) is a "red line" in clinical research. The authors chose to retract the paper to prevent others from potentially replicating a dangerous protocol.
  • Safety vs. Guidelines: The authors emphasize that they closely monitored patients and observed no decrease in renal function or immediate side effects. However, "no harm done" does not justify the violation of internationally accepted safety standards.
  • The Importance of Post-Publication Peer Review: This retraction was prompted by readers raising concerns after the article was in print. It serves as a reminder that the scientific process continues after publication, and the community acts as a final safeguard for medical ethics.
  • Gaps in Ethics Oversight: The note reveals a systemic lapse: the authors, the institutional ethics board that approved the study, and the initial peer reviewers all failed to catch a major safety contraindication before the study commenced.

Key Results

The primary "result" of this note is the formal withdrawal of the study from the academic record.

Quantitatively, the authors report that despite the high-risk protocol:

  • There was no reported decrease in the patients' renal function after the scans.
  • No patients developed symptoms of NSF during the follow-up period.

Qualitatively, the authors acknowledge that the study contravenes international guidelines and that the justification for using GBCAs in this specific patient population was insufficient.

Limitations and Future Work

The most glaring limitation was the authors' lack of awareness regarding the specific contraindications of Gadodiamide.

For future work in this sub-field, the retraction suggests a clear path:

  1. Non-Contrast Alternatives: Researchers looking at myocardial fibrosis in ESRD patients should prioritize non-contrast MRI techniques (such as T1 mapping without contrast) or other imaging modalities that do not carry the risk of NSF.
  2. Strict Adherence to GBCA Guidelines: If contrast is absolutely necessary, researchers must use newer-generation "macrocyclic" GBCAs, which have a much lower risk profile for NSF, and provide robust justification for why alternative imaging was not feasible.
  3. Enhanced Ethics Training: There is a clear need for more rigorous screening of clinical trial protocols involving high-risk populations to ensure that "standard" procedures in one field (cardiology) do not violate "black box" warnings in another (nephrology).

Summary updated

Abstract

This article has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1186/s12872-020-01688-7.
BibTeX
@inproceedings{xu2020retraction,
  author = {Huayan Xu and Zhigang Yang and Yi Zhang and Wanlin Peng and Chunchao Xia and Zhenlin Li and Yong He and Rong Xu and Li Rao and Ying Peng and Yuming Li and Hongling Gao and Yingkun Guo},
  title = {{Retraction Note: Prognostic value of heart failure in hemodialysis-dependent end-stage renal disease patients with myocardial fibrosis quantification by extracellular volume on cardiac magnetic resonance imaging}},
  booktitle = {BMC},
  year = {2020},
  doi = {10.1186/s12872-020-01688-7},
}

Loading related content...

Figure